Framingham, MA, United States of America

Manish Tandon

This inventor holds 24 USPTO granted patents and 4 published patent applications and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Arqule, Inc.. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Manish Tandon. Retrieved from https://idiyas.com/inventor/manish-tandon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 4)

% Patents Active = 79.2

EPO Patents = 6 (Patent Applications = 17)

Average Co-Inventor Count = 6.3

ph-index = 6

Forward Citations = 86(Granted Patents)

Company Filing History:

24 out of 104

Arqule, Inc.

patents

Years Active: 2009-2021

Loading Chart...

Areas of Expertise:

Amino-Pyrrolopyrimidinone

Imidazopyridinyl-Aminopyridine

Pyrazolo-Pyrimidine

Quinone Prodrugs

P38 MAP Kinase

Pharmaceutical Compositions

Substituted Compounds

Cancer Treatment

Tumor Targeting

Inhibitors

Synthesis

Chemical Methods

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11020398 - Amino-pyrrolopyrimidinone compounds and methods of use thereof (2021-06-01),

2. 8962619 - Substituted imidazopyridinyl-aminopyridine compounds (2015-02-24),

3. 8906928 - Substituted pyrazolo-pyrrolo-pyridine-dione compounds (2014-12-09),

4. 8815854 - Substituted imidazopyridinyl compounds (2014-08-26),

5. 8614228 - Quinone prodrug compositions and methods of use (2013-12-24),

6. 8609688 - Substituted imidazopyridinyl-aminopyridine compounds (2013-12-17),

7. 8580803 - Substituted pyrrolo-aminopyrimidine compounds (2013-11-12),

8. 8541407 - Substituted benzo-pyrido-triazolo-diazepine compounds (2013-09-24),

9. 8501770 - Substituted imidazopyridinyl-aminopyridine compounds (2013-08-06),

10. 8497276 - Substituted indolo-piperidine compounds (2013-07-30),

11. 8410144 - Substituted indolo-pyridinone compounds (2013-04-02),

12. 8357694 - Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds (2013-01-22),

13. 8349827 - Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds (2013-01-08),

14. 8343983 - Substituted pyrazolo-pyrimidine compounds (2013-01-01),

15. 8273754 - Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds (2012-09-25),

Title: **Manish Tandon: Innovator in Pharmaceutical Chemistry**

Introduction

Manish Tandon is a highly accomplished inventor located in Framingham, Massachusetts. With a strong focus on pharmaceutical chemistry, Tandon has been instrumental in developing compounds that have significant implications in treating various diseases. With a remarkable portfolio of 24 patents, his contributions to the field are both innovative and impactful.

Latest Patents

Among his latest inventions, Tandon has created amino-pyrrolopyrimidinone compounds. This particular patent relates to a compound represented by a specific formula that modulates the activity of BTK (Bruton’s tyrosine kinase), which is crucial in treating various diseases where BTK plays a role. Additionally, he has worked on substituted imidazopyridinyl-aminopyridine compounds. This patent focuses on methods for synthesizing these compounds, as well as their pharmaceutical compositions, aimed at treating cell proliferative disorders, such as cancer.

Career Highlights

Manish Tandon currently works with Arqule, Inc., a prominent company dedicated to advancing innovative medicines for patients. His role at Arqule has allowed him to contribute to groundbreaking research and refine his skills in pharmacology and medicinal chemistry, leading to numerous successful patent applications.

Collaborations

Throughout his career, Tandon has had the opportunity to collaborate with talented professionals in the industry. Notable coworkers include Mark Anthony Ashwell and Jean-Marc Lapierre, with whom he has shared valuable insights and expertise, enhancing his work and fostering a collaborative environment.

Conclusion

Manish Tandon’s significant contributions through his patents demonstrate his commitment to innovation in pharmaceutical research. His work is not only advancing the scientific community but also has the potential to improve patient care and treatment outcomes in the healthcare sector. As he continues his journey at Arqule, Tandon's future endeavors are eagerly anticipated by peers and professionals alike.

Profile summary based on public USPTO records.